CN113109575A - 40 antibody kit for monitoring human immune state and application - Google Patents
40 antibody kit for monitoring human immune state and application Download PDFInfo
- Publication number
- CN113109575A CN113109575A CN202110413977.6A CN202110413977A CN113109575A CN 113109575 A CN113109575 A CN 113109575A CN 202110413977 A CN202110413977 A CN 202110413977A CN 113109575 A CN113109575 A CN 113109575A
- Authority
- CN
- China
- Prior art keywords
- sample
- kit
- horizon
- cells
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012544 monitoring process Methods 0.000 title abstract description 13
- -1 gdTCR Proteins 0.000 claims abstract description 59
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 27
- 239000011886 peripheral blood Substances 0.000 claims abstract description 27
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 22
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 22
- 210000002865 immune cell Anatomy 0.000 claims abstract description 16
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims abstract description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 14
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims abstract description 10
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims abstract description 10
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims abstract description 9
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims abstract description 9
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 claims abstract description 8
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims abstract description 8
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 claims abstract description 7
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims abstract description 7
- 238000004458 analytical method Methods 0.000 claims abstract description 7
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 3
- 108010002386 Interleukin-3 Proteins 0.000 claims abstract description 3
- 238000001514 detection method Methods 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 34
- 229910052751 metal Inorganic materials 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 18
- 239000002184 metal Substances 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 13
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000004448 titration Methods 0.000 claims description 10
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 9
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 9
- 238000012083 mass cytometry Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000012118 Alexa Fluor 750 Substances 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- JLDSMZIBHYTPPR-UHFFFAOYSA-N Alexa Fluor 405 Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.C12=C3C=4C=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C1=CC=C3C(S(=O)(=O)[O-])=CC=4OCC(=O)N(CC1)CCC1C(=O)ON1C(=O)CCC1=O JLDSMZIBHYTPPR-UHFFFAOYSA-N 0.000 claims description 6
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 claims description 6
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 claims description 6
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 claims description 6
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000010355 oscillation Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000012192 staining solution Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 239000012114 Alexa Fluor 647 Substances 0.000 claims description 4
- 239000012115 Alexa Fluor 660 Substances 0.000 claims description 4
- 239000012116 Alexa Fluor 680 Substances 0.000 claims description 4
- 239000012117 Alexa Fluor 700 Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 3
- 239000012110 Alexa Fluor 594 Substances 0.000 claims description 3
- 239000012112 Alexa Fluor 633 Substances 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 238000007664 blowing Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 238000004043 dyeing Methods 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 210000005087 mononuclear cell Anatomy 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 3
- VDBJCDWTNCKRTF-UHFFFAOYSA-N 6'-hydroxyspiro[2-benzofuran-3,9'-9ah-xanthene]-1,3'-dione Chemical compound O1C(=O)C2=CC=CC=C2C21C1C=CC(=O)C=C1OC1=CC(O)=CC=C21 VDBJCDWTNCKRTF-UHFFFAOYSA-N 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 210000003462 vein Anatomy 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kit capable of detecting human immune states and application thereof, wherein the kit can be used for monitoring changes of human immune states, and comprises 40 labeled antibodies, wherein the 40 antibodies are monoclonal antibodies CD45, gdTCR, CD196/CCR 45, CD45, IgD, CD123/IL-3 45 85 45, CD 45/IL-2 36274/PD-L45, CD278/ICOS, CD45, CD45 45, CD197/CCR 45, CD11 45, CD152/CTLA-4, CD161, CD185/CXCR 45, CD66 45, CD 183/45, CD 3645, CD127/IL-7Ra, CD/PD-1, CD45, CD 36194, CD45, CD. The kit disclosed by the invention can be used for rapidly and accurately carrying out deep analysis on immune cells in peripheral blood by collecting the peripheral blood through veins on a multi-color flow cytometer or a mass spectrometer flow cytometer platform by utilizing 40 antibodies, and has strong specificity and high sensitivity.
Description
Technical Field
The invention relates to a detection kit in the fields of cell biology and biomedical detection, in particular to a detection kit for detecting human immune state, which can be used for evaluating human immune state and disease risk prediction.
Background
Peripheral blood lymphocytes are classified into T lymphocytes, B lymphocytes, NK lymphocytes according to biological function and cell surface antigen expression. T lymphocytes are mainly involved in cellular immunity and express CD3 antigen; b cells are primarily involved in humoral immunity, expressing the CD19 antigen; NK cells express CD16 and/or CD56 and exert cytotoxic effects in the body spontaneously independent of antigen stimulation. The T cells comprise helper T cells (Th) and suppressor T cells (Ts), which respectively express CD4 and CD8, and the Th cells can be divided into multiple types such as Th1, Th2, Th17, Th19, Th22, Tfh, Treg and the like according to the difference of transcription factors and secreted cytokines, and can be divided into initial T cells, effector T cells and memory T cells according to the different activation states of the T cells.
Immunomodulatory therapy has achieved clinical efficacy in a variety of cancers, autoimmune diseases and inflammation, allergy, widely used therapeutic strategies such as hematopoietic stem cell transplantation, immune checkpoint suppression, CART therapy, etc., many immunotherapeutic trials have been accompanied by immune monitoring, providing important cues of immune cell status from immune subpopulations and single cell levels. Monitoring peripheral blood immune cells is an important tool for immunodiagnosis and biomarker screening, and is expected to better understand immune pathogenesis and pathology and determine new therapeutic targets.
Disclosure of Invention
The invention aims to provide a kit for detecting the immune state of a human body, and also provides a preparation method of the kit and application of the kit in detecting the immune state of the human body.
In order to achieve the purpose, the invention adopts the technical scheme that: a kit comprising 40 antibodies labeled, said 40 antibodies being monoclonal antibodies CD45, gdTCR, CD196/CCR 45, CD45, IgD, CD123/IL-3 45, CD 45/IL-2 36274/PD-L45, CD278/ICOS, CD45, CD 3645 45, CD197/CCR 45, CD11 45, CD152/CTLA-4, CD161, CD185/CXCR 45, CD66 45, CD183/CXCR 45, CD45 45, CD127/IL-7Ra, CD279/PD-1, CD45, CD 194/45, CD279/PD 45, CD 3611.
The kit disclosed by the invention deeply detects T and B lymphocytes, NK cells, monocytes, dendritic cells and subgroups in peripheral blood, and comprises a series of cell activation markers and immune checkpoint proteins. The application to monitoring and comprehensive deep analysis of the patient's peripheral immune system status during clinical studies not only helps elucidating the immune cell mechanisms of new therapies, but it also helps predict the patient's risk of disease progression by identifying activation states, immune checkpoint features, and helps predict clinical response to treatment.
As a preferred embodiment of the kit of the present invention, the 40 antibodies are labeled with fluorescein or metal element, respectively. The antibody in the kit of the present invention is preferably labeled with fluorescein or metal element, but not limited to fluorescein and metal element. The 40 antibodies are labeled with different fluorescein or 40 different metal elements, respectively.
As a preferred embodiment of the kit according to the invention, the fluorescein is selected from the group consisting of Biotin, FITC, PE, TRITC, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Cy7, APC/efour 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlourr 710, PE/Cy7, PE/Cy5, PE/zzzle, PE-CF594, Pacific, Brillit Villiant 600, Brilliant 788, Brilliant yellow 650, Brilliant 702, Brilliant 600, Brilliant yellow 750, Bright Violet 702, Bright Fluant 750, Bright Flutter 750, Bright yellow 7, Bright yellow 750, Bright, eFluor 506, eFluor 660, eFluor 710, eFluor 780, BD Horizon BB515, BD Horizon PE-CF594, BD Horizon BV421, BD Horizon BV480, BD Horizon BV510, BD Horizon BV605, BD Horizon BV650, BD Horizon BV711, BD Horizon BV786, BD Horizon BUV395, BD Horizon BUV496, BD Horizon BUV737, BD Horizon BUV805, BD Horizon APC R700, Cy3, Cy5, Cy 7.
As a preferred embodiment of the kit of the invention, the metal element is selected from 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, Yb 176, 197Au, 198Pt, 209 Bi.
In a preferred embodiment of the kit of the present invention, the antibody in the kit is labeled with a metal element, and the labeling of the antibody with the metal element corresponds to the following:
| serial number | Channel | Antibodies | Serial number | Channel | Antibodies |
| 1 | 89Y | CD45 | 21 | 159Tb | CD11c |
| 2 | 115ln | CD3 | 22 | 160Gd | CD33 |
| 3 | 141Pr | CD56 | 23 | 161Dy | CD152/CTLA-4 |
| 4 | 142Nd | gdTCR | 24 | 163Dy | CD161 |
| 5 | 143Nd | CD196/CCR6 | 25 | 164Dy | CD185/CXCR5 |
| 6 | 144Nd | CD14 | 26 | 165Ho | CD66b |
| 7 | 145Nd | IgD | 27 | 166Er | CD183/CXCR3 |
| 8 | 146Nd | CD123/IL-3R | 28 | 167Er | CD94 |
| 9 | 147Sm | CD85j | 29 | 168Er | CD57 |
| 10 | 148Nd | CD19 | 30 | 169Tm | CD45RO |
| 11 | 149Sm | CD25/IL-2R | 31 | 170Er | CD127/IL-7Ra |
| 12 | 150Nd | CD274/PD-L1 | 32 | 171Yb | CD279/PD-1 |
| 13 | 151Eu | CD278/ICOS | 33 | 172Yb | CD38 |
| 14 | 152Sm | CD39 | 34 | 173Yb | CD194/CCR4 |
| 15 | 153Eu | CD27 | 35 | 174Yb | CD20 |
| 16 | 154Sm | CD24 | 36 | 175Lu | CD16 |
| 17 | 155Gd | CD45RA | 37 | 176Yb | HLA-DR |
| 18 | 156Gd | CD86 | 38 | 197Au | CD4 |
| 19 | 157Gd | CD28 | 39 | 198Pt | CD8a |
| 20 | 158Gd | CD197/CCR7 | 40 | 209Bi | CD11b |
In a preferred embodiment of the kit of the present invention, the labeled 40 antibodies each have a volume percentage of 0.5-80.5% in the kit.
The 40 monoclonal antibodies in the kit are not limited to antibody clone numbers, fluorescent label colors of the antibodies, mass numbers of metal labels or other antibody labeling and detecting methods.
In addition, the invention also provides a preparation method of the kit, which comprises the following steps:
(1) labeling the antibody with fluorescein or metal element;
(2) performing antibody titration;
(3) and (4) subpackaging the labeled antibody according to the titration result.
In the preparation method of the kit, the antibody is firstly subjected to fluorescence or metal labeling, then the use amount of the antibody is determined by titration, and finally the metered labeled antibody is put into a reagent bottle, uniformly mixed and sealed, and the fluorescent antibody needs to be stored in a dark place.
Finally, the invention also provides the application of the kit in detecting the immune state of the human body.
The kit can be used for detecting the immune cells in the peripheral blood, and the proportion of the immune cells in the peripheral blood is distinguished by the unique protein expression characteristics on the surfaces of various immune cells.
As a preferred embodiment of the application of the kit of the present invention in the detection of the immune state of a human body, when the kit is used for detecting the immune state of the human body, a detection sample is from the peripheral blood of the human body, and the human body comprises people of all ages.
As a preferred embodiment of the application of the kit of the invention in the detection of the immune state of a human body, the kit is used for the in-depth detection of T and B lymphocytes and NK cells, monocytes, dendritic cells and subpopulations in human peripheral blood and comprises a series of cell activation markers and immune checkpoint proteins.
As a preferred embodiment of the application of the kit of the invention in detecting the immune state of a human body, the kit comprises the following steps in detecting the immune state of the human body:
(1) isolating peripheral blood mononuclear cells;
(2) detecting the expression abundance of the antigen corresponding to the lymphocyte antibody in the peripheral blood of the sample by using a flow cytometer or a mass spectrometer;
(3) and (3) performing dimensionality reduction analysis and operation by using an algorithm according to the abundance of each protein expression of immune cells in peripheral blood, and determining the immune state of the detection sample.
When the kit is applied to detection of the immune state of a human body, the used detection instrument is preferably but not limited to a fluorescence flow cytometer and a mass spectrum flow cytometer.
As a preferred embodiment of the application of the kit of the present invention in detecting the immune state of a human body, the flow cytometry detection in the step (2) comprises the following steps:
1) collecting not less than 100 mu L of human peripheral blood as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) respectively sucking 0.5-5 mu L of 40 reagents from the kit into a flow tube, adding the detection sample into the flow tube, and uniformly mixing the detection sample with the flow tube by oscillation to obtain a first pre-sample;
3) incubating the first pre-sample at normal temperature in a dark place for 10-20 min, preferably 15min, or at 2-8 ℃ for 20-40 min, preferably 30min to obtain a second pre-sample;
4) adding 300 ul-2 mL of erythrocyte lysate into the second pre-sample, oscillating and uniformly mixing, and incubating for 2min at normal temperature in a dark place to obtain a third pre-sample;
5) centrifuging the third pre-sample to obtain a fourth pre-sample; the centrifugation condition of the centrifugation is 500 Xg, normal temperature and 5 min;
6) discarding the supernatant of the fourth pre-sample, and adding PBS buffer solution into the residual sample after discarding the supernatant to carry out resuspension to obtain a detection sample;
7) and (4) detecting the detection sample on a flow cytometer.
As a preferred embodiment of the application of the kit of the present invention in detecting the immune state of a human body, the mass spectrometry flow cytometry detection in the step (2) comprises the following steps:
1) collecting not less than 5mL of peripheral blood of a human body as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) separating a detection sample by using lymphocyte separating medium to obtain mononuclear cells;
3) counting the cells to 1-3 × 106A cell;
4) using PBS buffer solution to prepare 194Pt (1mM) dead and live staining solution with the final concentration of 0.25 mu M, taking 50 ul-1.5 ml of 194Pt dead and live staining solution to resuspend cells, preferably 100 mu L, and staining for 5min on ice;
5) adding 100 ul-1.5 ml FACS Buffer (preferably 500 ul) into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
6) adding 20 ul-1.5 ml of sealing liquid, preferably 50ul, into each sample, resuspending the cells, and sealing on ice for 20 min-1 h, preferably 20 min;
7) respectively sucking 0.5-4 mu L of 40 metal antibodies from the kit into a centrifugal tube, and adjusting the total volume to 50 mu L by using confining liquid;
8) adding the detection sample into the centrifuge tube, wherein the total volume is 100 mu L, and uniformly mixing the detection sample and the centrifuge tube by oscillation;
9) gently blowing and beating the uniformly mixed cells, and dyeing on ice for 20-60 min, preferably 30 min;
10) adding 1mL of FACS Buffer into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
11) preparing Ir dye solution with final concentration of 100-500 nM, preferably 250nM, by using Fix and Perm Buffer, taking 200 mu L-1.5 ml of heavy suspension cells from each sample, and incubating for 1h at room temperature;
12)12) discarding the supernatant, using 500 ul-1.5 mL FACS Buffer, preferably 1mL, resuspending the cells, centrifuging at 2-8 ℃ for 800g/5min, discarding the supernatant, resuspending the cells with deionized water, and detecting the detection sample on a mass cytometry (MS) flow cytometer.
The kit provided by the invention provides a group of 40-color antibody combination schemes by utilizing 40 antibodies, single-tube detection of a single sample is realized on a multi-color flow cytometer or mass spectrum flow cytometer platform by utilizing the kit provided by the invention, deep analysis can be carried out on immune cells through bioinformatics analysis, and the immunocompetence of a physical examiner can be effectively monitored. By adopting the kit, the immune cells in peripheral blood can be rapidly and accurately deeply analyzed by collecting the peripheral blood through veins; the kit is suitable for monitoring the immune state of physical testers in all age groups. The kit has strong specificity and high sensitivity; each antibody can be accurately measured only by 0.5 mu L-4 ul, and the repeatability reproducibility of the measured data is good; the sample is easy to obtain, the report period is short, and the detection time and the cost are effectively reduced.
With the change of modern human life style, many people are in a sub-health state, the kit disclosed by the invention can be used for deeply analyzing peripheral blood lymphocytes, establishing an organism immune state scoring system, evaluating the autoimmunity, assisting in diagnosing certain diseases, analyzing a pathogenesis, observing a curative effect and detecting prognosis. The kit can find whether a physical examiner has the problem of abnormal immune state through detection, and for people with abnormal immune state, the kit can condition the people by adjusting the self state or adopting a medical means to intervene and enhance the immunity under the guidance of doctors.
Drawings
FIG. 1 is a diagram showing the results of mass spectrometry validity detection of 40 antibodies in the kit of the present invention.
Detailed Description
To better illustrate the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
The kit for monitoring the immune state of the human body, provided by the invention, is suitable for physical examination persons of all ages. The kit analyzes the protein expression abundance of peripheral blood immune cells by using a flow cytometer or a mass spectrometer, and evaluates the immune state by being assisted with bioinformatics analysis.
The inventor builds a scheme of monitoring basic antibody such as AluTC, AluTC or Fluoron, AluTC or Fluoron, AldTc or Fluoron, or AldTc, CD45, CD45 45, CD197/CCR 45, CD11 45, CD152/CTLA-4, CD161, CD185/CXCR 45, CD66 45, CD183/CXCR or CXCR 45, CD183/CXCR 45, CD 279/IL-7 Ra, CD279/PD-1, CD45, CD194/CCR 45, CD 279/IL-7 Ra, AluTC or Fluoron or AluTC or Fluoron or, Alexa Fluor 647, Alexa Fluor660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Alexa Fluor750, APC/Cy7, APC/efour 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlour 710, PE/Cy7, PE/Cy5, PE/Dazzle 594, PE-CF594, Pacific Blue, Brilliant Violet 421, Brilliant Violet 510, Brilliant Violet 570, Brilliant Violet 605, Brilliant Violet 650, Brilliant Violet 711, BD 594, BD 750, Brilliant Violet 785, Brilliant 436, Super Brilliant 600, Brilliant Super horir Fluor 650, Hongzon Fluor 650, Brilliant BV, Brilliant Fluor 410, Brilliant BV Fluor 650, Brilliant BV, Brilliant Fluor 450, Brilliant BV, Brilliant Fluor 410, Brilliant BV, BD horizons BUV395, BD horizons BUV496, BD horizons BUV737, BD horizons BUV805, BD horizons APC R700, Cy3, Cy5, Cy7 and the like flow cytometer detectable fluorescence matching, or 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb 173, 173Yb 174, 175Lu, Yb 176, 197Au 198, Pt, 209Bi and the like flow cytometer detectable fluorescence matching. The mass spectrum flow detection method is used for detecting basic samples of hundreds of healthy people, an 'immune state' model which is suitable for Chinese and reflects the steady state of peripheral blood lymphocytes is established, and the correlation between the proportion of the individual peripheral blood lymphocytes and the immune state can be accurately evaluated, so that whether the immunity is abnormal or disordered or not is judged, and the individual is helped to carry out correct health management.
The 40 kinds of monoclonal antibodies labeled with fluorescein or metal elements used in the present invention are commercially available, for example, but not limited to, U.S. Biolegend, BD, R & D, and the like.
The fluorescein used in the present invention is commercially available, for example, but not limited to, the brand name ThermoFisher, BD, etc.
The metal elements used in the present invention are commercially available, such as, but not limited to, the U.S. Fluidigm brand.
The present inventors monitored immune status based on a number of experimental studies and established corresponding flow cytometry or mass cytometry protocols, and tested human immune status by combining labeled antibodies of CD127(IL-7Ra), CD14, CD16, CD19, CD197(CCR7), CD 7 (IL-2Ra), CD 7, CD40 7, CD 7, HLA-DR, TCRgd, CD11 7, CD123(IL-3R), CD161, CD183(CXCR 7), CD185(CXCR 7), CD196(CCR 7), CD 7, CD 36278 (ICOS), CD279(PD-1), CD 7, CD 3685 7, CD IgD, CD152 (CD-4), CD274 (PD-L7), CD 7, CD 36194, fonxp 194, graxt, CD 36194, CD 7, CD 36194.
The human immune state monitoring method is suitable for physical testers of all ages, the optimal dosage of the antibody is determined by antibody titration and other methods, the dosage of a single antibody is within the range of 0.1-4 ul, ideal grouping can be achieved, and the detection effect is expected; the sample obtained when the immune state monitoring model is established is taken from peripheral blood of a healthy person; and (3) taking 200 healthy human samples to carry out expression abundance detection of antigens corresponding to peripheral blood immune cells.
When the kit is used for detecting the human body immunity state, the peripheral blood immune cells of a healthy human sample are firstly detected. The specific method comprises the following steps:
the kit of the invention is adopted for detection, the kit of the invention contains 40 marked antibodies, the 40 antibodies are CD45, CD3, CD56, gdTCR, CD196/CCR6, CD14, IgD, CD123/IL-3R, CD85j, CD19, CD25/IL-2R, CD274/PD-L1, CD278/ICOS, CD39, CD27, CD24, CD45RA, CD86, CD28, CD197/CCR7, CD11c, CD33, CD152/CTLA-4, CD161, CD185/CXCR5, CD66b, CD183/CXCR3, CD94, CD57, CD45RO, CD127/IL-7Ra, CD279/PD-1, CD38, CD194/CCR4, CD20, CD16, HLA-DR, CD4, CD8a, CD11b monoclonal antibodies, the antibodies are not limited to antibody clone numbers, and the antibodies are respectively marked with different fluorescein suitable for flow cytometry detection or 40 metal elements suitable for mass cytometry detection.
Preferably, the fluorescein is selected from Biotin, FITC, PE, TRITC, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Alexa Fluor750, APC/Cy7, APC/eflor 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlourr 710, PE/Cy7, PE/Cy5, PE/Dazzle 594, PE-CF Blue 780, Pacific 780, Brilliant Villiant Ville 421, Brilliant Ville 605, Brilliant Ville 510, Brilliant 600, Brilliant vitr Fluoret 750, Bright et 750, Bright Fluoret 750, Bright ad 750, Bright Fluoret 750, Bright et 650, Bright ad 750, Bright ad 450, Bright Fluoret 750, Bright ad 450, Bright et 450, Bright Fluor Bright Fluoret 750, Bright Fluor, Any one of BD Horizon BB515, BD Horizon PE-CF594, BD Horizon BV421, BD Horizon BV480, BD Horizon BV510, BD Horizon BV605, BD Horizon BV650, BD Horizon BV711, BD Horizon BV786, BD Horizon BUV395, BD Horizon BUV496, BD Horizon BUV737, BD Horizon BUV805, BD Horizon APC R700, Cy3, Cy5, and Cy 7.
Preferably, the metal element is selected from any one of 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 197Au, 198Pt and 209 Bi.
Preferably, the volume percentage of each labeled antibody in the 40 labeled antibodies in the kit is 0.5-80.5%.
The preparation method of the kit comprises the following steps:
1) carrying out fluorescence or metal labeling on the antibody;
2) performing antibody titration;
3) and (4) subpackaging the labeled antibody according to the titration result.
After the kit is prepared, the storage condition is 2-8 ℃, and the fluorescent antibody kit needs to be stored in a dark place. After the preparation of the kit is completed, the human peripheral blood from the 200 samples is detected.
Preferably, the sample to be tested is tested by a flow cytometer, and the preparation for flow test of the sample to be tested comprises the following steps:
1) collecting not less than 100 mu L of human peripheral blood as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) respectively sucking 0.5-5 mu L of 40 reagents from the kit into a flow tube, adding the detection sample into the flow tube, and uniformly mixing the detection sample with the flow tube by oscillation to obtain a first pre-sample;
3) incubating the first pre-sample at normal temperature in a dark place for 10-20 min, preferably 15min, or at 2-8 ℃ for 20-40 min, preferably 30min to obtain a second pre-sample;
4) adding 300 ul-2 mL of erythrocyte lysate into the second pre-sample, oscillating and uniformly mixing, and incubating for 2min at normal temperature in a dark place to obtain a third pre-sample;
5) centrifuging the third pre-sample to obtain a fourth pre-sample; the centrifugation condition of the centrifugation is 500 Xg, normal temperature and 5 min;
6) discarding the supernatant of the fourth pre-sample, adding PBS buffer (pH7.4) into the residual sample after discarding the supernatant, and resuspending to obtain a detection sample;
7) and (4) detecting the detection sample on a flow cytometer.
Preferably, the mass cytometry is adopted to detect a sample to be detected, and the mass flow detection preparation of the sample to be detected comprises the following steps:
1) collecting not less than 5mL of peripheral blood of a human body as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) separating a detection sample by using lymphocyte separating medium to obtain mononuclear cells;
3) counting the cells to 1-3 × 106A cell;
4) using PBS buffer solution (pH7.4) to prepare 194Pt (1mM) dead and live staining solution with final concentration of 0.25. mu.M, taking 50 ul-1.5 ml of 194Pt dead and live staining solution to re-suspend cells, preferably 100. mu.L, and staining on ice for 5 min;
5) adding 100 ul-1.5 ml FACS Buffer (preferably 500 ul) into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
6) adding 20 ul-1.5 ml of sealing liquid, preferably 50ul, into each sample, resuspending the cells, and sealing on ice for 20 min-1 h, preferably 20 min;
7) respectively sucking 0.5-4 mu L of 40 metal antibodies from the kit into a centrifugal tube, and adjusting the total volume to 50 mu L by using confining liquid;
8) adding the detection sample into the centrifuge tube, wherein the total volume is 100 mu L, and uniformly mixing the detection sample and the centrifuge tube by oscillation;
9) gently blowing and beating the uniformly mixed cells, and dyeing on ice for 20-60 min, preferably 30 min;
10) adding 1mL of FACS Buffer into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
11) preparing Ir dye solution with final concentration of 100-500 nM, preferably 250nM, by using Fix and Perm Buffer, taking 200 mu L-1.5 ml of heavy suspension cells from each sample, and incubating for 1h at room temperature;
12) discarding the supernatant, using 500 ul-1.5 mL FACS Buffer, preferably 1mL, resuspending the cells, centrifuging at 2-8 ℃ for 800g/5min, discarding the supernatant, resuspending the cells with deionized water, and detecting the detection sample on a mass cytometry.
The application of the kit is based on a flow cytometer or a mass spectrometer, the kit is used for detecting T and B lymphocytes and NK cells, monocytes, dendritic cells and subgroups in human peripheral blood, and the kit comprises a series of cell activation markers and immune checkpoint proteins. Through the detection results of the immune cells in the peripheral blood of the 200 samples, namely the expression abundance of the corresponding protein detected by 40 antibodies of the testee, dimension reduction analysis and machine learning calculation are carried out, and an immune state scoring system is established for detecting and evaluating the autoimmune states of various crowds.
The invention also provides application of the kit in monitoring the immune state of a human body.
Preferably, when the kit is used for monitoring the immune state of a human body, the kit can detect the immune state of the human body, and the specific detection comprises the following steps:
1) detecting T and B lymphocytes and NK cells, monocytes, dendritic cells and subpopulations of the detection sample by flow cytometry or mass cytometry, and comprising a series of cell activation markers and immune checkpoint proteins;
2) and (3) according to the expression condition of each protein, evaluating the immune state of the detection sample by contrasting the steady state model.
Example 1
According to one embodiment of the kit, the 40 fluorescent or metal-labeled monoclonal antibodies are prepared, according to the titration result of the antibodies, the antibody concentration which can be clearly grouped or accords with the performance declared by a manufacturer is selected, each antibody is added into 1.5ml of centrifuge tube according to the corresponding concentration, the total volume is made up to 50 mu L by using a sealing solution, and the fluorescent antibodies need to be stored in a dark place, so that 1 person of the product is obtained.
Example 2
Preparation of the kit:
preparing the 40 marked monoclonal antibodies, selecting the antibody concentration which can be clearly grouped or accords with the performance declared by a manufacturer according to the titration result of the antibodies, respectively mixing 1-100 parts of fluorescent antibodies according to the corresponding concentration, and storing in a dark place to obtain 1-100 parts of the product.
After the kit is prepared, the usage amount of the product is marked on the kit.
The mass spectrometry validity detection results of 40 antibodies in the kit are shown in figure 1.
Through experiments, a sample of the subject is detected by using the mass spectrometry flow antibody kit of the above embodiment.
A mass spectrometric positive ratio of 40 markers for a sample using the same kit is shown in table 1. B019-B028 represent different numbers of subjects, and the abundance of various protein markers in immune cells is shown to be different in different individuals through Table 1.
TABLE 1 detection results of 40 markers for different individuals
The kit for detecting the human immune state provided by the invention utilizes the expression abundance of corresponding proteins detected by 40 antibodies of a subject to perform dimensionality reduction analysis and machine learning calculation, and establishes an immune state scoring system for detection and evaluation of various groups of people.
200 samples of volunteers were monitored and compared with the physical condition of the volunteers using the kit for monitoring immune status provided by the present invention. As shown in table 2, when the immune status score is less than 0.5, it indicates that the subjects have good autoimmune status, good aging degree of immune system, and low immune injury degree, and is matched with the subjects having no bad life habits and good physical conditions; when the immune state score is more than 0.5, the autoimmune state of the subject is lower than the normal level, the aging degree of the immune system is high, the immune injury degree is high, and the immune system corresponds to the physical conditions of 'disordered work and rest, irregular diet and easy fatigue'.
Table 2 survey table of immune status test results and general physical condition of physical examination patients;
the above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, and any simple modification, equivalent change and modification made to the above embodiment according to the technical spirit of the present invention are still within the scope of the technical solution of the present invention.
Claims (10)
1. A kit comprising 40 antibodies labeled, said 40 antibodies being monoclonal antibodies CD45, gdTCR, CD196/CCR 45, CD45, IgD, CD123/IL-3 45, CD 45/IL-2 36274/PD-L45, CD278/ICOS, CD45, CD45 45, CD197/CCR 45, CD11 45, CD152/CTLA-4, CD161, CD185/CXCR 45, CD66 45, CD183/CXCR 45, CD45 45, CD127/IL-7Ra, CD279/PD-1, CD45, CD194/CCR 45, CD 45-CD 45, DR 3611, HLA 3611.
2. The kit of claim 1, wherein the 40 antibodies are labeled with fluorescein or metal element, respectively.
3. The kit of claim 2, wherein said fluorescein is selected from the group consisting of Biotin, FITC, PE, TRITC, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Alexa Fluor750, APC/Cy7, APC/eflor 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlourr 710, PE/Cy7, PE/Cy5, PE/zzzle, PE-594 CF594, Pacific 594, Brillit Villi 421, Brillit 600, Brilliant Violet 702, Bright Flutter 750, Bright yellow 7, Bright yellow 750, Bright yellow 8926, Bright yellow 750, eFluor 506, eFluor 660, eFluor 710, eFluor 780, BD Horizon BB515, BD Horizon PE-CF594, BD Horizon BV421, BD Horizon BV480, BD Horizon BV510, BD Horizon BV605, BD Horizon BV650, BD Horizon BV711, BD Horizon BV786, BD Horizon BUV395, BD Horizon BUV496, BD Horizon BUV737, BD Horizon BUV805, BD Horizon APC R700, Cy3, Cy5, Cy 7.
4. The kit of claim 2, wherein the metallic element is selected from the group consisting of 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 197Au, 198Pt, 209 Bi.
5. The kit of claim 1, wherein each of the 40 labeled antibodies is present in the kit in an amount of 0.5 to 80.5% by volume.
6. The method for preparing the kit according to any one of claims 1 to 5, wherein the method comprises the following steps:
(1) labeling the antibody with fluorescein or metal element;
(2) performing antibody titration;
(3) and (4) subpackaging the labeled antibody according to the titration result.
7. Use of a kit according to any one of claims 1 to 5 for detecting the immune status of a human.
8. Use of a kit according to claim 7 for detecting the immune status of a human, comprising the steps of:
(1) isolating peripheral blood mononuclear cells;
(2) detecting the expression abundance of the antigen corresponding to the lymphocyte antibody in the peripheral blood of the sample by using a flow cytometer or a mass spectrometer;
(3) and (3) performing dimensionality reduction analysis and operation by using an algorithm according to the abundance of each protein expression of immune cells in peripheral blood, and determining the immune state of the detection sample.
9. The use of the kit of claim 8 for detecting the immune status of a human, wherein the flow cytometry detection in step (2) comprises the steps of:
1) collecting not less than 100 mu L of human peripheral blood as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) respectively sucking 0.5-5 mu L of 40 reagents from the kit into a flow tube, adding the detection sample into the flow tube, and uniformly mixing the detection sample with the flow tube by oscillation to obtain a first pre-sample;
3) incubating the first pre-sample at normal temperature in a dark place for 10-20 min, preferably 15min, or at 2-8 ℃ for 20-40 min, preferably 30min to obtain a second pre-sample;
4) adding 300 ul-2 mL of erythrocyte lysate into the second pre-sample, oscillating and uniformly mixing, and incubating for 2min at normal temperature in a dark place to obtain a third pre-sample;
5) centrifuging the third pre-sample to obtain a fourth pre-sample; the centrifugation condition of the centrifugation is 500 Xg, normal temperature and 5 min;
6) discarding the supernatant of the fourth pre-sample, and adding PBS buffer solution into the residual sample after discarding the supernatant to carry out resuspension to obtain a detection sample;
7) and (4) detecting the detection sample on a flow cytometer.
10. The use of the kit of claim 8 for detecting the immune status of a human, wherein the mass spectrometric flow cytometry detection in step (2) comprises the steps of:
1) collecting not less than 5mL of peripheral blood of a human body as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) separating a detection sample by using lymphocyte separating medium to obtain mononuclear cells;
3) counting the cells to 1-3 × 106A cell;
4) using PBS buffer solution to prepare 194Pt (1mM) dead and live staining solution with the final concentration of 0.25 mu M, taking 50 ul-1.5 ml of 194Pt dead and live staining solution to resuspend cells, preferably 100 mu L, and staining for 5min on ice;
5) adding 100 ul-1.5 ml FACS Buffer (preferably 500 ul) into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
6) adding 20 ul-1.5 ml of sealing liquid, preferably 50ul, into each sample, resuspending the cells, and sealing on ice for 20 min-1 h, preferably 20 min;
7) respectively sucking 0.5-4 mu L of 40 metal antibodies from the kit into a centrifugal tube, and adjusting the total volume to 50 mu L by using confining liquid;
8) adding the detection sample into the centrifuge tube, wherein the total volume is 100 mu L, and uniformly mixing the detection sample and the centrifuge tube by oscillation;
9) gently blowing and beating the uniformly mixed cells, and dyeing on ice for 20-60 min, preferably 30 min;
10) adding 1mL of FACS Buffer into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
11) preparing Ir dye solution with final concentration of 100-500 nM, preferably 250nM, by using Fix and Perm Buffer, taking 200 mu L-1.5 ml of heavy suspension cells from each sample, and incubating for 1h at room temperature;
12) discarding the supernatant, using 500 ul-1.5 mL FACS Buffer, preferably 1mL, resuspending the cells, centrifuging at 2-8 ℃ for 800g/5min, discarding the supernatant, resuspending the cells with deionized water, and detecting the detection sample on a mass cytometry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110413977.6A CN113109575A (en) | 2021-04-16 | 2021-04-16 | 40 antibody kit for monitoring human immune state and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110413977.6A CN113109575A (en) | 2021-04-16 | 2021-04-16 | 40 antibody kit for monitoring human immune state and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113109575A true CN113109575A (en) | 2021-07-13 |
Family
ID=76718123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110413977.6A Pending CN113109575A (en) | 2021-04-16 | 2021-04-16 | 40 antibody kit for monitoring human immune state and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113109575A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113777327A (en) * | 2021-09-13 | 2021-12-10 | 北京大学人民医院 | Antibody composition for leukemia/lymphoma immunophenotyping primary screening and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108226016A (en) * | 2018-01-12 | 2018-06-29 | 浙江普罗亭健康科技有限公司 | The mass spectrum flow cytometer detection kit of the accurate parting of tumor vaccine cells subgroup |
| CN109254147A (en) * | 2018-10-12 | 2019-01-22 | 东莞暨南大学研究院 | Human peripheral blood immune cell function fully assesses kit and appraisal procedure |
| CN109490544A (en) * | 2018-09-13 | 2019-03-19 | 浙江博真生物科技有限公司 | A kind of kit and its application for detecting the human immunity age |
| CN110191948A (en) * | 2016-11-02 | 2019-08-30 | 巴塞尔大学 | Identifiable cell surface variant is immunized for cell therapy |
| CN110412287A (en) * | 2019-07-11 | 2019-11-05 | 上海宸安生物科技有限公司 | One kind being based on single celled immunocyte parting quantitative analysis method |
-
2021
- 2021-04-16 CN CN202110413977.6A patent/CN113109575A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110191948A (en) * | 2016-11-02 | 2019-08-30 | 巴塞尔大学 | Identifiable cell surface variant is immunized for cell therapy |
| CN108226016A (en) * | 2018-01-12 | 2018-06-29 | 浙江普罗亭健康科技有限公司 | The mass spectrum flow cytometer detection kit of the accurate parting of tumor vaccine cells subgroup |
| CN109490544A (en) * | 2018-09-13 | 2019-03-19 | 浙江博真生物科技有限公司 | A kind of kit and its application for detecting the human immunity age |
| CN109254147A (en) * | 2018-10-12 | 2019-01-22 | 东莞暨南大学研究院 | Human peripheral blood immune cell function fully assesses kit and appraisal procedure |
| CN110412287A (en) * | 2019-07-11 | 2019-11-05 | 上海宸安生物科技有限公司 | One kind being based on single celled immunocyte parting quantitative analysis method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113777327A (en) * | 2021-09-13 | 2021-12-10 | 北京大学人民医院 | Antibody composition for leukemia/lymphoma immunophenotyping primary screening and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113125718A (en) | 45 antibody kit for monitoring human immune state and application | |
| CN113125755A (en) | 9 antibody kit for monitoring human immune state and application thereof | |
| US20060275752A1 (en) | Multiparameteric method for assessing immune system status | |
| Payne et al. | OMIP-063: 28-color flow cytometry panel for broad human immunophenotyping | |
| CN112331344B (en) | Immune state evaluation method and application | |
| CN113125733A (en) | 42 antibody kit for monitoring human immune state and application thereof | |
| CN108845129B (en) | Application of biomarker of active tuberculosis diseases | |
| CN113125754A (en) | 23 antibody kit for monitoring human immune state and application | |
| CN115524490A (en) | HLA-DR + CD14 + CD56 + Use of monocytes for diagnosis in AA or HLH | |
| EP1019546B1 (en) | Methods for measurement of lymphocyte function | |
| CN115166252A (en) | Lymphocyte subset grouping and quantitative detection kit, detection method and application thereof | |
| US20200011865A1 (en) | Methods and kits for detecting basophil activation | |
| EP0603107B1 (en) | Procedure for the simultaneous quantification, in a single measurement, of the major types of human lymphocytes and their subsets | |
| CN113109575A (en) | 40 antibody kit for monitoring human immune state and application | |
| US20110070599A1 (en) | Method for Screening of Active Tuberculosis | |
| Grant et al. | Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients | |
| US5968755A (en) | Methods for determining T-cell profiles of immunocompromised subjects | |
| Dock et al. | Human immune compartment comparisons: optimization of proliferative assays for blood and gut T lymphocytes | |
| CN116559464A (en) | Immune response assessment system | |
| CN114121162A (en) | Method for evaluating immunity | |
| CN113125719A (en) | 6 antibody kit for monitoring human immune state and application | |
| CN114112868A (en) | Flow cytometry kit for monitoring tumor-related immune microenvironment and monitoring method | |
| EP3467497B1 (en) | Method for analyzing expression of smn protein nuclear body | |
| Park et al. | Single-color multitarget flow cytometry using monoclonal antibodies labeled with different intensities of the same fluorochrome | |
| CN110494750B (en) | Method for detecting effector regulatory T cell, device for analyzing effector regulatory T cell, system for analyzing effector regulatory T cell, and program |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210713 |